APYX
BULLISH
$3.63
Live
Apyx Medical Corporation · NASDAQ
Target $6.4
(+76.3%)
$0.76
52W Range
$4.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$148.94M
P/E
N/A
ROE
-76.1%
Profit margin
-21.2%
Debt/Equity
2.65
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
APYX exhibits a weak Piotroski F-Score of 1/9, signaling significant financial distress and poor operational health, with negative ROE, ROA, and high debt/equity. Despite this, the company demonstrates strong revenue growth (34.7% YoY) and a compelling earnings surprise history, with recent quarters beating estimates by an average of 33.74%. The stock is trading at a premium valuation (Price/Book: 10.43, Price/Sales: 2.82) but is supported by a strong analyst consensus of 'strong_buy' and a target price of $6.40, implying significant upside. Insider activity remains neutral, but the recent 1-year return of +249% reflects strong market momentum. The absence of a Graham Number and Altman Z-Score limits fundamental safety checks, but growth expectations appear to justify the valuation premium.
Key Strengths
Strong revenue growth of 34.7% YoY
Consistent earnings beat history with average surprise of 33.74% over last 4 quarters
High analyst consensus with 'strong_buy' rating and $6.40 target price
Significant recent price appreciation (+249% over 1 year)
High gross margin of 62.53% indicating pricing power and efficient production
Key Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor operational quality
Negative ROE (-76.15%) and ROA (-6.12%) reflect deep profitability issues
Debt/Equity ratio of 2.65 is high, especially for a company with negative earnings
No Altman Z-Score available, but the financial health metrics suggest distress risk
Negative profit margin (-21.22%) and lack of positive operating cash flow or free cash flow data
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
44
Moderate
45
82
70
25
0
AI Verdict
cautiously bullish
Key drivers: Strong revenue and earnings surprise momentum, High growth expectations priced in, Positive technical trend and strong price performance
Confidence
85%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 2.82 is below sector average of 137.13% revenue growth, suggesting potential undervaluation relative to growth
- Forward P/E of -12.74 implies market pricing in future profitability
Watchpoints
- No Graham Number or intrinsic value estimate available
- Price/Book of 10.43 is extremely high for a company with negative ROE and profitability
- Lack of positive cash flow metrics undermines valuation reliability
Future
82/100
Ref Growth rates
Positives
- 34.7% YoY revenue growth is robust and consistent
- Recent Q/Q EPS growth of +40.0% and YoY EPS growth of +75.0% indicate accelerating profitability
- Strong earnings surprise history suggests strong execution and guidance accuracy
Watchpoints
- Forward P/E is negative, indicating no near-term earnings visibility
- No free cash flow or operating cash flow data to validate growth sustainability
Past
70/100
Ref Historical trends
Positives
- 25 quarters of earnings data show consistent beat rate (3/4 in last 4 quarters)
- Average earnings surprise of 33.74% over last 4 quarters is exceptional
- Recent quarters show improving EPS trends despite negative baseline
Watchpoints
- Long-term negative earnings trend with persistent losses
- Historical losses and negative ROE/ROA indicate structural profitability issues
Health
25/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High current and quick ratios (5.00 and 4.16) suggest strong short-term liquidity
- No immediate cash crunch risk despite negative earnings
Watchpoints
- Piotroski F-Score of 1/9 is extremely low, indicating severe financial weakness
- Negative ROE (-76.15%) and ROA (-6.12%) signal poor capital efficiency
- Debt/Equity of 2.65 is high for a non-profitable firm
- No Altman Z-Score available, but financials suggest distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength score of 0/100 confirms no dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.63
Analyst Target
$6.4
Upside/Downside
+76.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for APYX and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
APYX
Apyx Medical Corporation
Primary
|
-68.5% | +28.3% | +249.0% | +72.9% | -7.4% | +16.4% |
|
NYXH
Nyxoah SA
Peer
|
-85.9% | -65.9% | -43.6% | -44.6% | +7.1% | +11.4% |
|
AGEN
Agenus Inc.
Peer
|
-93.5% | -88.0% | +124.2% | -10.7% | +36.6% | +18.4% |
|
TLSA
Tiziana Life Sciences Ltd
Peer
|
-51.0% | +16.4% | +7.1% | -38.3% | 0.0% | +5.2% |
|
EMPG
Empro Group Inc.
Peer
|
+299.1% | +299.1% | +299.1% | -2.2% | 0.0% | 0.0% |
APY
Apyx Medical Corporation
Primary
5Y
-68.5%
3Y
+28.3%
1Y
+249.0%
6M
+72.9%
1M
-7.4%
1W
+16.4%
NYX
Nyxoah SA
Peer
5Y
-85.9%
3Y
-65.9%
1Y
-43.6%
6M
-44.6%
1M
+7.1%
1W
+11.4%
AGE
Agenus Inc.
Peer
5Y
-93.5%
3Y
-88.0%
1Y
+124.2%
6M
-10.7%
1M
+36.6%
1W
+18.4%
TLS
Tiziana Life Sciences Ltd
Peer
5Y
-51.0%
3Y
+16.4%
1Y
+7.1%
6M
-38.3%
1M
0.0%
1W
+5.2%
EMP
Empro Group Inc.
Peer
5Y
+299.1%
3Y
+299.1%
1Y
+299.1%
6M
-2.2%
1M
0.0%
1W
0.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-12.74
PEG Ratio
N/A
P/B Ratio
10.43
P/S Ratio
2.82
EV/Revenue
3.02
EV/EBITDA
-27.58
Market Cap
$148.94M
Profitability
Profit margins and return metrics
Profit Margin
-21.21%
Operating Margin
0.06%
Gross Margin
62.53%
ROE
-76.15%
ROA
-6.12%
Growth
Revenue and earnings growth rates
Revenue Growth
+34.7%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.65
High debt
Current Ratio
5.0
Strong
Quick Ratio
4.16
Excellent
Cash/Share
$0.76
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-10
$-0.03
+46.4% surprise
2025-11-06
$-0.05
+51.2% surprise
2025-08-07
$-0.09
+3.6% surprise
Healthcare Sector Comparison
Comparing APYX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-76.15%
This Stock
vs
-88.14%
Sector Avg
-13.6%
(Below Avg)
Profit Margin
-21.21%
This Stock
vs
-16.28%
Sector Avg
+30.3%
(Superior)
Debt to Equity
2.65
This Stock
vs
2.66
Sector Avg
-0.4%
(Lower)
Revenue Growth
34.7%
This Stock
vs
124.04%
Sector Avg
-72.0%
(Slower)
Current Ratio
5.0
This Stock
vs
4.47
Sector Avg
+11.7%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
APYX
Apyx Medical Corporation
|
BULLISH | $148.94M | - | -76.1% | -21.2% | $3.63 | |
|
NYXH
Nyxoah SA
|
BEARISH | $147.36M | - | -111.0% | -% | $3.38 | Compare |
|
AGEN
Agenus Inc.
|
BEARISH | $144.21M | - | -% | -32.9% | $3.99 | Compare |
|
TLSA
Tiziana Life Sciences Ltd
|
BEARISH | $153.97M | - | -232.3% | -% | $1.21 | Compare |
|
EMPG
Empro Group Inc.
|
NEUTRAL | $143.05M | 192.89 | 66.3% | 13.7% | $17.36 | Compare |
APYX
Apyx Medical Corporation
BULLISH
Mkt Cap
$149M
P/E
-
ROE
-76.1%
Price
$3.63
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-27 | ROMAN SHAWN DAVID | Chief Operating Officer | Option Exercise | 12,000 | $21,600 |
ROMAN SHAWN DAVID
Chief Operating Officer
2026-01-27
12,000 shares
·
$21,600
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
Craig-Hallum
2026-03-11
Buy
Buy
BTIG
2026-03-11
Neutral
Buy
Roth Capital
2025-12-16
Buy
Citizens
2025-11-12
Market Perform
Market Outperform
Past News Coverage
Recent headlines mentioning APYX from our newsroom.
Newest → oldest
No matching news yet.